Clinical Trial Update: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating olaparib as maintenance therapy in BRCA-mutated, platinum-sensitive ovarian cancer patients who achieved complete or partial response…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brca-mutated Ovarian Cancer
• Ovarian Cancer
• Ovarian Cancer Following Complete or Partial Response to Platinum-based Chemotherapy
• Platinum-sensitive Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Platinum Sensitive, BRCA Mutated | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-02-07